# Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc. is a company headquartered in San Diego, CA, United States.

## Company overview

- **Legal name:** Cidara Therapeutics, Inc.
- **Former names in filing history:** K2 THERAPEUTICS, INC. (2014-06-17 to 2015-02-04)
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** San Diego, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001610618

## About

Cidara Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001610618, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2025-03-06, it reported annual revenue of USD 1,275,000; net income of USD -169,827,000; total assets of USD 214,796,000 for the fiscal period ended 2024-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2024-12-31)

- **Revenue:** $1.3M (USD 1,275,000)
- **Net income:** -$169.8M (USD -169,827,000)
- **Total assets:** $214.8M (USD 214,796,000)
- **Cash and equivalents:** $189.8M (USD 189,825,000)
- **Operating cash flow:** -$176.5M (USD -176,533,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $63.9M (USD 63,905,000)
- **Net income:** -$22.9M (USD -22,931,000)
- **Total assets:** $67.0M (USD 67,030,000)
- **Cash and equivalents:** $35.8M (USD 35,778,000)
- **Operating cash flow:** -$22.4M (USD -22,432,000)
- **Later filings:** Revenue: shown as originally filed; later filings report different values for the same periods.

### FY2022 (period ended 2022-12-31)

- **Net income:** -$29.8M (USD -29,799,000)
- **Total assets:** $47.6M (USD 47,593,000)
- **Cash and equivalents:** $32.7M (USD 32,731,000)
- **Operating cash flow:** -$28.5M (USD -28,473,000)
- **Later filings:** Net income, Total assets: shown as originally filed; later filings report different values for the same periods.

### FY2021 (period ended 2021-12-31)

- **Net income:** -$42.5M (USD -42,467,000)
- **Total assets:** $75.3M (USD 75,325,000)
- **Cash and equivalents:** $59.7M (USD 59,680,000)
- **Operating cash flow:** -$25.2M (USD -25,232,000)

## Recent SEC filings

- Form 8-K — filed 2026-01-07 — period 2026-01-07 — 8-K
- Form 8-K — filed 2025-11-14 — period 2025-11-13 — 8-K
- Form 10-Q — filed 2025-11-06 — period 2025-09-30 — CIDARA THERAPEUTICS, INC. FORM 10-Q
- Form 8-K — filed 2025-11-06 — period 2025-11-06 — CIDARA THERAPEUTICS, INC. FORM 8-K
- Form 8-K — filed 2025-10-06 — period 2025-09-30 — CIDARA THERAPEUTICS, INC. FORM 8-K
- Form 8-K — filed 2025-09-24 — period 2025-09-24 — 8-K
- Form 10-Q — filed 2025-08-07 — period 2025-06-30 — CIDARA THERAPEUTICS, INC. FORM 10-Q
- Form 8-K — filed 2025-08-07 — period 2025-08-07 — CIDARA THERAPEUTICS, INC. FORM 8-K
- Form 8-K — filed 2025-06-25 — period 2025-06-24 — 8-K
- Form 8-K — filed 2025-06-24 — period 2025-06-24 — 8-K
- Form 8-K — filed 2025-06-23 — period 2025-06-23 — 8-K
- Form 8-K — filed 2025-06-20 — period 2025-06-18 — CIDARA THERAPEUTICS, INC. FORM 8-K

---

Updated: 2026-10-23T20:09:28Z

Canonical page: https://altss.com/profile/cidara-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology